<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922389</url>
  </required_header>
  <id_info>
    <org_study_id>CNS-P0-V1</org_study_id>
    <nct_id>NCT00922389</nct_id>
  </id_info>
  <brief_title>A Clinical Trial on Diabetic Foot Using Peripheral Blood Derived Stem Cells for Treating Critical Limb Ischemia</brief_title>
  <official_title>A Randomized, Controlled, Parallel Design, Safety and Efficacy Study of Granulocyte Colony Stimulating Factor Mobilized Autologous Peripheral Blood Mononuclear Cell Therapy in Subjects With Diabetic Limb Ischemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beike Biotech India Pvt.ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beike Biotech India Pvt.ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the method (implanting stem cells derived&#xD;
      from peripheral blood after G-CSF mobilization) of treatment is safe and effective in the&#xD;
      management of diabetic foot ischemia, the therapeutic effect of stem cells is caused by&#xD;
      improving blood circulation in ischemic limb which would in turn promote ulcer healing,&#xD;
      prevent amputation of limb and relieve the Sevier pain of ischemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One devastating complication of diabetes is peripheral arterial disease (PAD) including&#xD;
      critical limb ischemia (CLI), which may result in limb loss. Epidemiological evidence&#xD;
      confirms an association between diabetes and increased prevalence of peripheral arterial&#xD;
      disease (PAD). The prevalence of peripheral vascular disease among the Indian diabetic&#xD;
      population is 13%.&#xD;
&#xD;
      This therapy provides a targeted approach i.e. by improving blood perfusion in the ischemic&#xD;
      area of the lower limb by inducing neovascularization, which would be further evaluated by&#xD;
      measuring the change in transcutaneous partial pressure of oxygen (TCpO2), NMR angiography of&#xD;
      local vessels, ulcer healing, pain relief, limb salvage, ABI index etc.&#xD;
&#xD;
      The specific design of the trial enables us to differentially study the effect of stem cell&#xD;
      on diabetic foot CLI as compared to G-CSF (granulocyte colony stimulating factor) in (one&#xD;
      control group) and standard therapy (in another control group), this study would also&#xD;
      evaluate the effect of stem cell dose.&#xD;
&#xD;
      Extracting stem cells from this method is far more easy to perform as compared to extracting&#xD;
      from bone marrow and is less painful for the patient as well.&#xD;
&#xD;
      The yield of mononuclear stem cell from peripheral blood is much higher as compared to bone&#xD;
      marrow and role of CD34+ cells in limb ischemia is not yet established in humans, therefore&#xD;
      this study would evaluate the dynamics of different types of mononuclear cells and its&#xD;
      correlation with the therapeutic effect.&#xD;
&#xD;
      This clinical trial highlights the safety of using G-CSF in diabetic CLI by having a separate&#xD;
      control group in which volunteers would be given only G-CSF through subcutaneous route, also&#xD;
      this would tell about the therapeutic effect if any attributable to it.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and laboratory parameters</measure>
    <time_frame>12 Months after the theraphy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trans Cutaneous partial pressure of Oxygen: TCpO2</measure>
    <time_frame>12 Months post thraphy</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Diabetic Foot</condition>
  <condition>Critical Limb Ischemia</condition>
  <condition>Leg Ulcers</condition>
  <arm_group>
    <arm_group_label>G-CSF + Stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No stem cell group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standerd theraphy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Any therapy for diabetic foot CLI which is routinely practiced and accepted in India</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>will receive G-CSF and peripheral blood derived mononuclear cells</intervention_name>
    <description>Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.</description>
    <arm_group_label>G-CSF + Stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>5 micrograms/kg/day for 4 days by subcutaneous route</description>
    <arm_group_label>No stem cell group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Therapy</intervention_name>
    <description>Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc</description>
    <arm_group_label>Standerd theraphy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetic patients with controlled blood sugar levels&#xD;
&#xD;
          -  Subject has an Ankle-brachial index &lt; 0.6&#xD;
&#xD;
          -  TCpO2 &lt; 30-45 mm Hg measured at the calf muscle&#xD;
&#xD;
          -  Subjects with unilateral or bilateral diabetic critical limb ischemia (reduced TCpO2&#xD;
             (&lt;30-45 mm Hg)) who are:&#xD;
&#xD;
               -  Non reconstructable PAD as assessed by a qualified vascular surgeon on case to&#xD;
                  case basis depending upon results of angiography and clinical judgment.&#xD;
&#xD;
               -  Subjects not likely to be benefited with prostaglandin E1&#xD;
&#xD;
          -  Lower extremity Ulcers of Grade II of Wagner's classification&#xD;
&#xD;
          -  All subjects test negative for human immunodeficiency virus, hepatitis B virus,&#xD;
             hepatitis C virus and treponema pallidum and their respective antibodies&#xD;
&#xD;
          -  S Creatinine &lt; 2.5 mg/dL&#xD;
&#xD;
          -  All female participants in the study should be practicing a medically acceptable form&#xD;
             of contraception (IUD, the pill etc.)&#xD;
&#xD;
          -  Subject has had previous conservative treatment which resulted in little or no&#xD;
             improvement&#xD;
&#xD;
          -  Subject has had no stem cell treatment within the past 6 months o Subject is competent&#xD;
             to provide informed consent and follow study procedures and instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All the subject below age 18 years and above 65 years.&#xD;
&#xD;
          -  The presence of Ischemic ulcers with infectious symptoms anywhere on the lower&#xD;
             extremity (Grade 3 and above of Wagner classification would be excluded from the study&#xD;
             in the screening period)&#xD;
&#xD;
          -  Diabetes mellitis with HbA1c &gt; 8.5% or associated with proliferative retinopathy&#xD;
&#xD;
          -  Any past or present malignancy&#xD;
&#xD;
          -  Susceptibility to severe allergic reactions or a history of severe allergic reactions&#xD;
&#xD;
          -  Recent occurrence (within 3 months) of myocardial infarction or brain infarction&#xD;
&#xD;
          -  Coronary angioplasty within the past 1 year&#xD;
&#xD;
          -  Atrial fibrillation or presence of mechanical mitral prosthetic valve&#xD;
&#xD;
          -  Presence of uncontrolled systemic infection or its ongoing treatment&#xD;
&#xD;
          -  Existing vital organ dysfunctions, including heart, lung or kidneys&#xD;
&#xD;
          -  Coagulation disorders such as hemophilia, etc&#xD;
&#xD;
          -  Use of any medication relevant to revascularization or perfusion&#xD;
&#xD;
          -  Lactating female with a breastfeeding child&#xD;
&#xD;
          -  A positive pregnancy test in female subjects&#xD;
&#xD;
          -  A presence of any other significant medical risk or a suspicion of future&#xD;
             non-compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Anoop Misra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fortis FLT.LT.Rajan Dhall Hospital ,New Delhi, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr.DAI .</last_name>
    <role>Study Director</role>
    <affiliation>Beike Biotech</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr.Kumar Ramsamudara</last_name>
    <phone>0091 11 29552056</phone>
    <email>drkumar@ensindia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr.Prateek Gupta</last_name>
    <phone>0091 11 29552056</phone>
    <email>drprateek@ensindia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fortis FLT.LT.Rajan Dhall Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110 070</zip>
        <country>India</country>
      </address>
    </facility>
    <investigator>
      <last_name>Dr.Anoop Misra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 16, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <last_update_submitted>June 16, 2009</last_update_submitted>
  <last_update_submitted_qc>June 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>Beike Biotech India Pvt.ltd</organization>
  </responsible_party>
  <keyword>Diabetes Complications</keyword>
  <keyword>Lower limb ischemia</keyword>
  <keyword>Adult stem cells</keyword>
  <keyword>peripheral blood stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

